Press Releases
Cell Signaling Technology Announces Alliance with AstraZeneca to Provide Rabbit Monoclonal Technologies for Biomarker Assays to Support Therapeutic Oncology Development Programs.
Danvers, MA, December 20, 2006 – Cell Signaling Technology, Inc. (CST) announced today an alliance with AstraZeneca under which it will employ its novel and proprietary rabbit monoclonal antibody (RmAb) technologies to develop high specificity and high affinity RmAbs to AstraZeneca oncology targets. CST will apply its expertise and capabilities in assay development to perform rigorous validation of RmAbs for applications important to the advancement of AstraZeneca’s lead small molecule therapeutics. CST has recently developed and optimized proprietary technologies for producing RmAbs that show improved affinity, specificity and clone stability. AstraZeneca will benefit from CST’s RmAb capabilities through the alliance, in which CST will validate antibodies and immunoassays for monitoring target and small molecule activity.
“CST is very excited to form this RmAb development alliance with AstraZeneca, as we have worked previously with them on a series of projects involving our core strengths in antibody and assay development and application of our PhosphoScan® proteomics discovery platform,” said Christopher Bunker, CST’s Director of Pharma Services. “This alliance is a great opportunity for CST in that it will utilize our well-established antibody validation expertise combined with our new RmAb technology.”
Dr. Les Hughes, AstraZeneca’s Global Vice President for Cancer and Infection Research, added “The objective of this collaboration is to identify antibodies, with the necessary affinity and specificity, that enable the development of robust assays for decision making purposes in Cancer Discovery. Given CST’s expertise in developing high performance antibodies, we expect our collaboration goals to be achieved.”
About Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST’s phospho-specific antibodies are validated in multiple assay platforms and are critical reagents in all stages of pharmaceutical drug discovery and development. CST’s new and proprietary RmAb technologies have been developed and optimized by CST to deliver higher value RmAb reagent products and contract services for research and drug development markets focused on cellular phosphorylation and signaling analysis profiles. Information on CST can be obtained at the Company’s website at www.cellsignal.com.
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $23.95 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
For more information, contact:
Eric Scharf
Cell Signaling Technology, Inc.
Director of Marketing
phone: (978) 867-2349
e-mail: escharf@cellsignal.com
